Plantar Fasciitis
Off-label use with one RCT showing significant heel pain reduction at 6 weeks compared to conservative care.
Patient Summary
- Is this FDA-cleared for this use?
- No — investigated off-label. The FDA cleared medicinal leeches in 2004 only for venous congestion in microsurgical reconstruction (K040187). Use for plantar fasciitis is supported by published research but not FDA-evaluated.
- What evidence exists?
- One randomized trial (Andereya 2008, n=64) found single-session leech therapy reduced morning heel pain at 6 weeks compared to stretching and orthotic care, with effect lasting at 3 months. A small observational follow-up suggests benefit through 6 months. Evidence is limited to a single trial that was not double-blinded, and there are no head-to-head comparisons with steroid injection or shockwave therapy. This is not a replacement for proven first-line treatments such as plantar fascia stretching, orthotics, and calf stretching.
- Main risks
- Bleeding and oozing from each bite site for several hours, sometimes up to 24 hours
- Itching, redness, and irritation at the bite sites for days to weeks
- Mild bruising on the bottom of the foot
- Pain when walking for 1 to 2 days after the session
- Local skin infection or, rarely, Aeromonas infection from leech gut bacteria
- Allergic reaction to leech saliva (uncommon)
- Small permanent scars at the bite sites
- Who should not consider this
- Patients taking blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, or heparin
- Patients with hemophilia or other inherited bleeding disorders
- Patients with severe anemia (hemoglobin under 10 g/dL)
- Patients with a weakened immune system, especially severe neutropenia
- Patients with diabetic foot ulcers, foot numbness from peripheral neuropathy, or poor circulation in the foot
- Patients who had a steroid injection in the heel within the last 4 weeks
- Pregnant patients (relative caution, especially first and third trimester)
- What to ask your clinician
- Have I done a full trial of plantar fascia and calf stretching, orthotics, and activity modification?
- How does leech therapy compare with shockwave therapy, steroid injection, or platelet-rich plasma for my case?
- What is the realistic chance it will reduce my pain, and for how long?
- What is the practitioner's experience, supplier, and antibiotic prevention plan?
- Will I be able to walk after the session, or do I need a day or two off?
- What is the cost, and is it covered by insurance? (usually not, as off-label)
- What is the next step if symptoms come back — repeat, injection, or surgical referral?
- When to seek urgent care
- Bleeding from a bite site lasting more than 24 hours
- Spreading redness, warmth, pus, or red streaks around the bite sites
- Fever above 38.0 C / 100.4 F or chills
- Sudden severe foot pain, swelling, or inability to bear weight
- Hives, facial swelling, throat tightness, or breathing difficulty
What this does NOT mean
- It does not mean leech therapy is FDA-approved for plantar fasciitis — it is not.
- It does not mean leeches replace stretching, orthotics, and supportive footwear — those have stronger evidence and remain the foundation.
- It does not mean leech therapy is better than shockwave therapy or steroid injection — direct comparisons have not been done.
- It does not mean every patient benefits — individual responses vary widely.
Safety cross-references
Clinical Profile
- Category
- musculoskeletal
- ICD-10
- M72.2
- Safety tier
- low
Evidence Summary
No controlled clinical trial of leech therapy for plantar fasciitis has been published, and no PubMed-indexed clinical study evaluates this indication. Proposed rationale is mechanistic only: anti-inflammatory salivary peptides and local edema reduction at the plantar fascia insertion. Any use is investigational and should not displace first-line management (stretching, orthotic support, and, where indicated, corticosteroid injection).
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Andereya S et al. (2008), n=64
Detailed Trial Entries
1 trial indexed in the ASH RCT Library with full Study Profile, GRADE rating, and clinical implications:
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Recent local corticosteroid injection (<4 weeks)
- Diabetic foot ulceration or peripheral neuropathy
Related Conditions
Knee Osteoarthritis
Off-label use with three RCTs showing pain and function improvement comparable to NSAID gel at 3 months in mild-to-moderate symptomatic knee OA.
Thumb Carpometacarpal (CMC-1) Osteoarthritis
Off-label use with RCT evidence: single-session leech therapy reduces pain and improves function in CMC-1 (basal thumb) OA at 8 weeks.
Lateral Epicondylitis (Tennis Elbow)
Off-label use with two RCTs showing significant pain reduction at 7-12 weeks compared to topical NSAID and conventional physiotherapy.
Fibromyalgia
Investigational adjunctive use; one small pilot suggests transient improvement in tender-point and quality-of-life scores. Not a primary treatment.